Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Petosemtamab Generates Early Clinical Activity and Tolerability in HNSCC

April 26th 2023

The bispecific antibody petosemtamab delivered responses with a manageable safety profile in patients with advanced head and neck squamous cell carcinoma.

Practical Considerations for Managing RR DTC With Systemic Therapy

April 24th 2023

Comprehensive insight on best practices in dose adjustment and adverse event management in patients receiving systemic therapy for RR DTC.

Patient Scenario 1: RR DTC Managed With Frontline Lenvatinib

April 24th 2023

Expert Marcia Brose, MD, PhD, reviews a patient case of radioiodine-refractory differentiated thyroid cancer (RR DTC) managed with frontline lenvatinib therapy.

Head and Neck, Breast cancer Research Highlights AACR Abstracts

April 20th 2023

University of Cincinnati Cancer Center researchers presented more than a dozen abstracts at the 2023 American Association for Cancer Research Annual Meeting, including findings that could advance treatments for head and neck and breast cancers.

Diagnosing DTC: Clinical Workup and Molecular Testing

April 17th 2023

Shared insight on best practices in diagnosing patients with differentiated thyroid cancer with a focus on histologic and molecular subtypes.

Overview on Differentiated Thyroid Cancer (DTC)

April 17th 2023

Opening discussion on the advent of differentiated thyroid cancer (DTC) and management, moderator Lori J. Wirth, MD, provides and overview of prevalence, subtypes, and prognosis.

FDA Grants Fast Track Designation to RRx-001 for Severe Oral Mucositis in Head and Neck Cancer

March 30th 2023

The FDA has granted a fast track designation to RRx-001 for the prevention and attenuation of severe oral mucositis associated with chemotherapy and radiation in patients with head and neck cancer.

PARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid Tumors

March 17th 2023

RBN-2397, a PARP7 inhibitor, was found to be well tolerated and have preliminary antitumor activity as monotherapy in patients with advanced solid tumors, including head and neck squamous cell carcinoma, breast cancer, and squamous cell carcinoma of the lung.

Post-Hoc Analysis Shows Overall Impact of Avasopasem in Reducing Burden of Severe Oral Mucositis in Head and Neck Cancer

March 16th 2023

Avasopasem manganese provided an overall clinical benefit vs placebo in reducing the burden of severe oral mucositis in patients with locally advanced head and neck cancer, according to a post-hoc generalized pairwise comparison analysis of the phase 3 ROMAN trial.

FDA Provides Guidance on Registrational Path for PDS0101 Triplet in HPV+, ICI-Refractory Head and Neck Cancer

February 27th 2023

The FDA has provided PDS Biotechnology Corporation with guidance on the required contents of a design for a potential registrational trial examining PDS0101 in combination with PDS0301 and an FDA-approved immune checkpoint inhibitor in patients with recurrent or metastatic human papillomavirus–positive, ICI-refractory head and neck cancer.

Toripalimab/Chemo Improves OS in Recurrent/Metastatic Nasopharyngeal Carcinoma in Final JUPITER-02 Trial Analysis

February 15th 2023

Toripalimab plus gemcitabine and cisplatin demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy alone as frontline therapy in patients with recurrent or metastatic nasopharyngeal carcinoma.

FDA Grants Priority Review to Avasopasem for Radiotherapy-Induced Severe Oral Mucositis

February 15th 2023

The FDA has granted priority review to the new drug application for avasopasem manganese as a treatment for radiotherapy-induced severe oral mucositis in patients with head and neck cancer undergoing standard-of-care treatment.

Docetaxel Added to Radiation Provides DFS, OS Benefit in Cisplatin-Ineligible HNSCC

February 2nd 2023

Radiation plus docetaxel improved disease-free survival and overall survival vs radiation alone in patients with head and neck squamous cell carcinoma unsuitable for cisplatin-based chemoradiation, regardless of patients’ prespecified prognostic groups, according to findings from a phase 2/3 trial.

HPV, PD-L1 Move to the Forefront of Biomarkers for Head and Neck Cancers

January 4th 2023

HPV status has broad applicability across head and neck cancers, whereas the clinical utility of PD-L1 expression remains a more nuanced question.

Toripalimab Plus Chemotherapy BLA Remains Under FDA Review for Recurrent or Metastatic Nasopharyngeal Carcinoma

January 3rd 2023

The FDA has not sent an action letter regarding the biologics license application for toripalimab in combination with chemotherapy as treatment for patients with recurrent or metastatic nasopharyngeal carcinoma.

PDS0101-Based Triplet Produces Prolonged OS in Refractory HPV+ Cancers

January 3rd 2023

Treatment with PDS0101 plus the tumor-targeting IL-12 fusion protein M9241 and bintrafusp alfa elicited encouraging overall survival data in patients with checkpoint inhibitor–naïve and –refractory advanced human papillomavirus–positive anal, cervical, head and neck, vaginal, and vulvar cancer.

PD-L1 Status Could Help Inform Patient Selection for IO-Based Therapy in HNSCC

December 15th 2022

Ranee Mehra, MD, discusses the significance of 5-year follow-up data and the subgroup analysis from KEYNOTE-048, the benefits and limitations of IO therapy in head and neck squamous cell carcinoma, and research aiming to expand the role of IO combination regimens in this space.

FDA Approval Sought for Avasopasem for Radiotherapy-Induced Severe Oral Mucositis in Head and Neck Cancer

December 12th 2022

Galera Therapeutics, Inc. has submitted a new drug application to the FDA that is seeking the approval ofavasopasem manganese for radiotherapy-induced severe oral mucositis in patients with head and neck cancer who are undergoing standard treatment.

Berzosertib Plus Standard Chemoradiation Elicits Promising Responses in Locally Advanced HNSCC

November 30th 2022

Aarti Bhatia, MD, discusses the rationale for investigating berzosertib in this patient population, key updates from the phase 1 trial, and how these findings support the need for continued research of novel regimens in HNSCC.

Cabozantinib/Atezolizumab Elicits Durable, Tolerable Clinical Activity in Advanced HNSCC

November 29th 2022

The combination of cabozantinib and atezolizumab generated rapid and durable responses in patients with advanced head and neck squamous cell carcinoma who received prior treatment with platinum-based chemotherapy.